Taysha Gene Therapies Advances Rett Syndrome Program; Shares Rise After Dosing Completion and Extended Data
Taysha Gene Therapies Inc saw its stock move higher in premarket trading after the company said it has finished dosing patients in the pivotal REVEAL trial for TSHA-102, a candidate for Rett syndrome. The firm disclosed longer-term clinical outcomes showing accumulating functional gains and reported no treatment-related serious adverse events throu…